Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

g the risk that CuraGen's pursuit of partnership opportunities will not proceed as planned or that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, as well as risk associated with the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's ability to comply with Nasdaq listing requirements, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to under the section "Risk Factors" in CuraGen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed with the Securities and Exchange Commission as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CRGN-P

Contacts:

Sean Cassidy

Vic
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... For its innovative modular Biomedical Research building ... Scientific has earned a Modular Building Institute (MBI) 2014 ... 30 categories, MBI,s contest is the commercial modular industry,s ... manufacturers, dealers, and product and service providers. ... of our team," said Dan Palmer , President ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
Breaking Medicine Technology:Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
... JOSE, Calif., June 13, 2011 SI-BONE, Inc. (San Jose, ... of a minimally invasive surgical (MIS) device to treat the ... surgeon training milestone for its iFuse Implant System® with over ... in Europe.  As a result, the medical community,s awareness of ...
... MIAMI, June 13, 2011 Sanomedics International Holdings, Inc. (Pink ... Chairman, with Keith Houlihan, Co-founder and President of Sanomedics ... appointment of Charlie Alvarez, Co-founder and President of Watermark ... "The addition of Charlie to the Sanomedics ...
Cached Medicine Technology:Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 2Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 3Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 4Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 2Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 3
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 NEWwoodworks, ... , is expanding their brand presence with a website ... over 20 years, NEWwoodworks has specialized in handcrafted cabinetry, ... interior furnishings. NEWwoodworks has earned a reputation for taking ... dare take on. They commonly craft with reclaimed wood, ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
(Date:7/31/2014)... 2014 The VitaSleep FDA cleared ... and provide an easier breathing capacity by slightly adjusting ... that people can breathe easier and helps reduce or ... so that it can meet the needs of each ... often shared by actual customer reviews. Johathan R. ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... 31, 2014 A program for anyone ... to the University of Colorado Anschutz Health and ... loss boot camp and transformation program. , “Extreme ... and Eyeworks USA, is an evidenced-based program inspired by ... by Eyeworks USA. This season, the show has participants ...
Breaking Medicine News(10 mins):Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... Blue branded dental plan,to central Pennsylvania (Lehigh Valley) ... BlueCross announced,today that it is acquiring Dominion Dental ... The move by the region,s,leading health insurer adds ... the Mid-Atlantic Region., "Helping to improve the ...
... Nov. 4 Hospira, Inc.,(NYSE: HSP ), ... announced that Christopher B. Begley, chairman and chief,executive ... Finance,and chief financial officer, will make a formal ... Conference on Wednesday, Nov. 12, 2008, in,Phoenix., ...
... PH ), the global leader in motion ... the purchase of Matrx nitrous oxide,delivery systems from ... to expand its geographic market space for dental ... American base of operations. The,product line will be ...
... Nov. 4 Allied Minds funds research to ... dermal fillers.,Allied Minds, a seed investment firm specializing ... research with Lawrence Berkeley National,Laboratory through creation of ... Eva Turley and Mina Bissell will develop a,technology ...
... of Minnesota Leverages Market Dynamics With New, Plan Offering ... ... NASHVILLE, Tenn., Nov. 4 ,HealthLeaders-InterStudy, a leading provider of managed ... the,national trend of moving from fully insured to self-insured health plans.,According ...
... Sold by A Uniquely-Trained Sales ... ... today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription for ... approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 as ...
Cached Medicine News:Health News:Capital BlueCross Acquires Dominion Dental 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 3Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:Minnesota Employers Buck National Trend and Largely Remain Fully-Insured 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3
... absolute knowledge. Access it with ... Diagnostic Workstation, uniting two trusted ... and Orbscan IIz Anterior Segment ... critically important data. Together they ...
... LADARWave® device gives you ... measure and display the ... individual eye. This capability ... a better understanding of ...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
...
Medicine Products: